The synthetic parasite-derived peptide GK1 increases survival in a preclinical mouse melanoma model.

PubWeight™: 0.77‹?›

🔗 View Article (PMC 3793655)

Published in Cancer Biother Radiopharm on July 10, 2013

Authors

Armando Pérez-Torres1, Jesús Vera-Aguilera, Juan Carlos Hernaiz-Leonardo, Eduardo Moreno-Aguilera, Diego Monteverde-Suarez, Carlos Vera-Aguilera, Daniel Estrada-Bárcenas

Author Affiliations

1: 1 Department of Cell and Tissue Biology, Facultad de Medicina, Universidad Nacional Autónoma de México , Distrito Federal, Mexico City, México .

Articles cited by this

Cancer statistics, 2006. CA Cancer J Clin (2006) 30.71

Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A (1993) 11.95

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol (2001) 10.20

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68

Interferons, immunity and cancer immunoediting. Nat Rev Immunol (2006) 8.23

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med (1985) 8.21

Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer (2004) 3.46

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med (1985) 3.05

Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell (2011) 2.96

Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer (2006) 2.44

Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A (1998) 2.29

An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin (2004) 2.18

UKCCCR guidelines for the welfare of animals in experimental neoplasia. Lab Anim (1988) 1.95

B16 as a mouse model for human melanoma. Curr Protoc Immunol (2001) 1.80

Melanoma therapy via peptide-targeted {alpha}-radiation. Clin Cancer Res (2005) 1.52

The eosinophil granule proteins in serum, but not the oxidative metabolism of the blood eosinophils, are increased in cancer. Br J Haematol (1997) 1.47

T cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas. J Immunol (1998) 1.44

Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res (2001) 1.44

Histological regression in primary cutaneous melanoma: recognition, prevalence and significance. Histopathology (1992) 1.39

Tumor immunotherapy by epicutaneous immunization requires langerhans cells. J Immunol (2008) 1.31

Long-term spontaneous regression of malignant melanoma with visceral metastases. Report of a case with immunologic profile. Cancer (1975) 1.17

A comparative study with various anesthetics in mice (pentobarbitone, ketamine-xylazine, carfentanyl-etomidate). Res Exp Med (Berl) (1984) 1.16

Pathogen-associated molecular pattern contamination as putative endogenous ligands of Toll-like receptors. J Endotoxin Res (2007) 1.09

Reduced tumorigenicity and augmented leukocyte infiltration after monocyte chemotactic protein-3 (MCP-3) gene transfer: perivascular accumulation of dendritic cells in peritumoral tissue and neutrophil recruitment within the tumor. J Immunol (1998) 1.04

Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model. J Immunother (2006) 1.01

Towards a Taenia solium cysticercosis vaccine: an epitope shared by Taenia crassiceps and Taenia solium protects mice against experimental cysticercosis. Infect Immun (1999) 1.01

Cysticercosis: identification and cloning of protective recombinant antigens. J Parasitol (1996) 0.99

The Tumor-Promoting Flow of Cells Into, Within and Out of the Tumor Site: Regulation by the Inflammatory Axis of TNFα and Chemokines. Cancer Microenviron (2011) 0.98

Dendritic cell immunotherapy for stage IV melanoma. Melanoma Res (2007) 0.95

Partial regression of primary cutaneous melanoma: is there an association with sub-clinical sentinel lymph node metastasis? Am J Dermatopathol (2003) 0.94

Human CD34+ cells engineered to express membrane-bound tumor necrosis factor-related apoptosis-inducing ligand target both tumor cells and tumor vasculature. Blood (2010) 0.92

Adjuvant therapy in melanoma. Onkologie (2003) 0.90

Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG. PLoS One (2010) 0.88

Malignant melanoma: current state of primary and adjuvant treatment. Crit Rev Oncol Hematol (2003) 0.88

A novel synthetic adjuvant effectively enhances the immunogenicity of the influenza vaccine. Vaccine (2005) 0.86

Anti-tumor activity of Acinetobacter baumannii outer membrane protein A on dendritic cell-based immunotherapy against murine melanoma. J Microbiol (2008) 0.84

Spontaneous regression of subcutaneous metastasis of cutaneous melanoma. Plast Reconstr Surg (1992) 0.83

Effective melanoma immunotherapy with interleukin-2 delivered by a novel polymeric nanoparticle. Mol Cancer Ther (2011) 0.83

Evidence for eosinophil activation in cancer patients receiving recombinant interleukin-4: effects of interleukin-4 alone and following interleukin-2 administration. Clin Cancer Res (1995) 0.83

Towards identification of the mechanisms of action of parasite-derived peptide GK1 on the immunogenicity of an influenza vaccine. Clin Vaccine Immunol (2009) 0.82

Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials. J Clin Oncol (2001) 0.82

Medical management of melanoma. Surg Clin North Am (2003) 0.82

Oral administration of immunopotentiator from Pantoea agglomerans 1 (IP-PA1) improves the survival of B16 melanoma-inoculated model mice. Exp Anim (2011) 0.82

Inhibition of growth of B16 murine malignant melanoma by exogenous interferon. Cancer Res (1980) 0.81

Complex cancer gene therapy in mice melanoma. Langenbecks Arch Surg (2002) 0.80

Inhibition of B16 melanoma growth and metastasis in C57BL mice by vaccination with a syngeneic endothelial cell line. J Exp Clin Cancer Res (2009) 0.80

Kinetics of cytokine expression in melanoma metastases classifies immune responsiveness. Int J Cancer (2001) 0.80

Anti-tumor activity of N-trimethyl chitosan-encapsulated camptothecin in a mouse melanoma model. J Exp Clin Cancer Res (2010) 0.79

A view to a kill: cytotoxic mechanisms of human polymorphonuclear leukocytes compared with monocytes and natural killer cells. Pathobiology (1990) 0.78

Antimetastatic, antineoplastic, and toxic effects of 4-hydroxycoumarin in a preclinical mouse melanoma model. Cancer Chemother Pharmacol (2009) 0.76